A board can question the commercial conclusion while respecting the evidence’s proper owner.

I would want a pharmaceutical board to understand what a strategic category establishes and what it leaves unresolved. A new therapeutic area, another geography or a larger initiative count can describe genuine activity without proving that the business has gained independent exposure or comparable evidence. My contribution would be to help the board examine those inferences, drawing on the professional conclusions it properly receives. The commercial question needs to be precise, but it does not displace medical, scientific, quality, safety or regulatory authority.

The acquisition case illustrates the distinction. A proposed portfolio with C$84 million in trailing annual revenue appeared to add therapeutic breadth while 45% depended on a familiar institutional purchasing group. I recommended declining after C$1.7 million in diligence expense. A board should hear why the corporate development team still valued the opportunity and why the concentration changed my recommendation. It should not be asked to accept that every concentrated transaction is unsuitable. The useful scrutiny concerns the dependence the institution is choosing and the reason it is prepared to accept it.

My own nine-brand mistake would shape that scrutiny. I had supported a diversification account before recognising that six brands shared one procurement route. The correction cost C$620,000 and required me to revise an interpretation colleagues had already used. On a board, I would need to remain open to a similar challenge to my own preferred description. Experience should make a director’s questions more informed, not make familiar categories immune to examination. I would want management and other directors to be able to explain where my analogy did not fit the business in front of us.

The geographical case also shows why board materials need more than a map. Two proposed markets carried a sales model with 56% through one distribution group. The C$135 million annual figure was an estimate at maturity, not a result. Preparing one market first with C$2.4 million expense gave up simultaneous momentum and did not settle every condition for the actual business. I would ask for the relevant professional assessment and keep that distinction visible when discussing what management was requesting. A commercial forecast cannot supply the authority of a product, contractual or operating conclusion.

Portfolio maturity requires comparable care. Nine early development activities and five established-medicine extensions may all belong in the strategy while needing different interpretations. I would not supply clinical probabilities or a valuation to make them easier to aggregate. I would seek the responsible specialists’ explanation of the evidence and ask how it informs the corporate choice. The board can take ambition seriously without requiring uncertainty to disappear from the presentation. A clear summary should make that uncertainty intelligible rather than hide it beneath a convenient total.

I would also examine the work that continues while long-term options remain open. The smaller portfolio’s C$4.2 million annual support estimate needed to remain visible beside its C$26 million revenue context. Those figures were not a complete margin account, and considering disposal did not by itself change present responsibilities. The board would need the professional and operating owners’ account of the actual undertaking. My strategic experience would help identify the gap between discussing an option and having completed a change, without promising an outcome or directing specialist work.

I have presented to the board as an executive since September 2017, with no statutory appointment in this fictional chronology. A first seat would require preparation for collective duties and an institution-specific assessment of suitability. I could initially discuss twenty-four annual days, subject to employer permission and the real workload. Employment, transaction, purchasing, distribution and personal connections would need disclosure and review, including circumstances that make participation unsuitable. No Indian databank registration or committee-chair qualification is claimed. The invented cases illustrate a possible contribution; a real candidacy would require verified evidence, appropriate advice and the governance preparation relevant to its circumstances.